UBS downgraded Immunovant (IMVT) to Neutral from Buy with a price target of $17, down from $38.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating
- Immunovant’s Strategic Advancements and Targeted Approach Drive Buy Rating
- Immunovant Announces New CEO Amid Strategic Shift
- Immunovant appoints Eric Venker as CEO, Girao as CFO
- Insider Moves: Cytokinetics, Bj’s, Gran Tierra, PBF, Immunovant